Boehringer Ingelheim looks to Korean biotech for next drug breakthroughs
Korea is moving beyond its traditional role as a market for medicines to become a source of pharmaceutical innovation, with local biotech partnerships and clinical research expected to play a larger role in global drug development, Boehringer Ingelheim CEO Shashank Deshpande says. “We do not anymore

Korea is moving beyond its traditional role as a market for medicines to become a source of pharmaceutical innovation, with local biotech partnerships and clinical research expected to play a larger role in global drug development, Boehringer Ingelheim CEO Shashank Deshpande says. “We do not anymore
💬 留言板 — 歡迎分享你的想法!
登入 Google 帳號即可留言